Mohamed Ghaith Al‐Kuwari
A5005784420- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- COVID-19 epidemiological studies
- SARS-CoV-2 detection and testing
- Global Cancer Incidence and Screening
- Physical Activity and Health
- Obesity, Physical Activity, Diet
- COVID-19 and healthcare impacts
- Colorectal Cancer Screening and Detection
- Viral gastroenteritis research and epidemiology
- Health and Well-being Studies
- Cervical Cancer and HPV Research
- Health and Lifestyle Studies
- Healthcare Systems and Reforms
- COVID-19 Pandemic Impacts
- Bacillus and Francisella bacterial research
- Mobile Health and mHealth Applications
- Global Maternal and Child Health
- Infection Control and Ventilation
- Global Public Health Policies and Epidemiology
- Viral Infections and Outbreaks Research
- Respiratory viral infections research
- Dietary Effects on Health
- Immune responses and vaccinations
Primary Health Care
2011-2025
Hamad General Hospital
2024
Qatar University
2014-2023
Weill Cornell Medical College in Qatar
2021-2022
Qatar Orthopaedic and Sports Medicine Hospital
2013-2021
Hamad Medical Corporation
2010-2021
World Health Organization - Pakistan
2021
Assiut University
2021
Ministry of Public Health
2009-2021
Cornell University
2021
BackgroundWaning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or disease 2019 (Covid-19) is a concern. The persistence BNT162b2 (Pfizer–BioNTech) effectiveness and in Qatar, where the B.1.351 (or beta) B.1.617.2 delta) variants have dominated incidence polymerase-chain-reaction testing done on mass scale, unclear.MethodsWe used matched test-negative, case–control study design to estimate any SARS-CoV-2 severe, critical, fatal case...
The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of omicron (B.1.1.529) variant is unclear.
Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence omicron (or B.1.1.529) variant severe acute respiratory syndrome 2 (SARS-CoV-2) have led to expedited efforts scale up booster vaccination. Protection conferred by doses BNT162b2 (Pfizer–BioNTech) mRNA-1273 (Moderna) vaccines in Qatar, as compared with two-dose primary series, is unclear.
Abstract SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection the second third/booster doses mRNA COVID-19 vaccines against infections in Qatar. BNT162b2 effectiveness was highest at 46.6% (95% CI: 33.4–57.2%) symptomatic 51.7% 43.2–58.9%) first three months after dose, but declined ~10% or below thereafter. Effectiveness rebounded 59.9% 51.2–67.0%) 43.7% 36.5–50.0%), respectively,...
Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons Qatar.All from April 16 to December 31, 2020 PCR-positive swab ≥14 days after first-positive antibody test investigated for evidence reinfection. Viral genome sequencing was conducted paired viral specimens confirm Incidence reinfection compared incidence infection complement those...
Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed the risk and incidence rate documented SARS-CoV-2 in a cohort laboratory-confirmed cases Qatar.All at least 1 polymerase chain reaction-positive swab that was ≥45 days after first positive were individually investigated for evidence reinfection. Viral genome sequencing paired viral specimens conducted to confirm reinfection.Out 133 266 cases, 243 persons (0.18%) had subsequent swab....
The overarching objective of this study was to provide the descriptive epidemiology severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in Qatar by addressing specific research questions through a series national epidemiologic studies. Sources data were centralized and standardized databases for SARS-CoV-2 infection. By July 10, 2020, 397,577 individuals had been tested using polymerase-chain-reaction (PCR), whom 110,986 positive, positivity cumulative rate 27.9% (95% CI...
Abstract Background The future of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic hinges on virus evolution and duration immune protection natural infection against reinfection. We investigated afforded by infection, effect viral evasion reinfection, in Qatar, between 28 February 2020 5 June 2022. Methods Three national, matched, retrospective cohort studies were conducted to compare incidence SARS-CoV-2 disease 2019 (COVID-19) severity among unvaccinated persons...
Abstract SARS-CoV-2 breakthrough infections in vaccinated individuals and those who had a prior infection have been observed globally, but the transmission potential of these is unknown. The RT-qPCR cycle threshold (Ct) value inversely correlated with viral load culturable virus. Here, we investigate differences Ct values across Qatar’s national cohorts primary infections, reinfections, BNT162b2 (Pfizer-BioNTech) mRNA-1273 (Moderna) infections. Our matched-cohort analyses randomly diagnosed...
Abstract There is significant genetic distance between SARS-CoV-2 Omicron (B.1.1.529) variant BA.1 and BA.2 sub-lineages. This study investigates immune protection of infection with one sub-lineage against reinfection the other in Qatar during a large wave, from December 19, 2021 to March 21, 2022. Two national matched, retrospective cohort studies are conducted estimate effectiveness (N = 20,994; BA.1-against-BA.2 study), 110,315; BA.2-against-BA.1 study). Associations estimated using Cox...
ABSTRACT Background Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is debated. We assessed risk and incidence rate of documented SARS-CoV-2 reinfection in a large cohort laboratory-confirmed cases Qatar. Methods All at least one PCR positive swab that ≥45 days after first-positive were individually investigated for evidence reinfection, classified as showing strong , good some or weak/no reinfection. Viral genome sequencing the paired viral specimens was...
We investigated what proportion of the population acquired severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and whether herd immunity threshold has been reached in 10 communities Qatar. The study included 4,970 participants during June 21-September 9, 2020. Antibodies against SARS-CoV-2 were detected by using an electrochemiluminescence immunoassay. Seropositivity ranged from 54.9% (95% CI 50.2%-59.4%) to 83.8% 79.1%-87.7%) across showed a pooled mean 66.1%...
The study objective was to the assess level of detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in urban population Qatar. Antibody testing performed on residual blood specimens for 112,941 individuals (∼10% Qatar's population) attending routine/other clinical care between May 12 and September 9, 2020. Seropositivity 13.3% (95% confidence interval [CI] = 13.1–13.6%) independently associated with sex, age, nationality, encounter type, date. Median optical...
Mathematical modeling constitutes an important tool for planning robust responses to epidemics. This study was conducted guide the Qatari national response severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic. The investigated epidemic's time-course, forecasted health care needs, predicted impact of social and physical distancing restrictions, rationalized justified easing restrictions.
Key messages and recommendations Thispopulation-based study documentsBNT162b2vaccine protection week-by-week after the first dose. 75% of against infection disease is reached 15-21 daysafter dose. Protection increased most rapidly hospitalization death slowest B.1.351infection.While one dose beyond 21 days could not be assessed, findings support delaying second vaccinedosein situations limited vaccine suppliesand high incidences.
Qatar experienced a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that disproportionately affected the craft and manual worker (CMW) population, who comprise 60% of total population. This study aimed to assess ever and/or current infection prevalence in this
Abstract The SARS-CoV-2 Delta (B.1.617.2) variant of concern is expanding globally. Here, we assess real-world effectiveness the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines against this in population Qatar, using a matched test-negative, case- control study design. any infection, symptomatic or asymptomatic, was 64.2% (95% CI: 38.1-80.1%) ≥14 days after first dose before second dose, but only 53.5% 43.9-61.4%) which large proportion fully vaccinated persons received their...
Abstract The SARS-CoV-2 pandemic resulted in considerable morbidity and mortality as well severe economic societal disruptions. Despite scientific progress, true infection severity, factoring both diagnosed undiagnosed infections, remains poorly understood. This study aimed to estimate age-stratified overall rates based on analysis of extensive epidemiological data for the pervasive epidemic Qatar, a country where < 9% population are ≥ 50 years. We show that severity fatality demonstrate...
Background The epidemiology of the SARS-CoV-2 B.1.1.7 (or Alpha) variant is insufficiently understood. This study’s objective was to describe introduction and expansion this in Qatar estimate efficacy natural infection against reinfection with variant. Methods findings Reinfections variants unknown status were investigated a national cohort 158,608 individuals prior PCR-confirmed infections 42,848 antibody-positive individuals. Infections also comparator 132,701 antibody-negative first...